Transmucosal Eliglustat Formulation for Improved Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing eliglustat formulations for Gaucher disease type 1 have low oral bioavailability due to significant first-pass metabolism, necessitating complex dosing regimens based on CYP2D6 genotype and frequent intravenous administration.
Innovation Solution
A transmucosal pharmaceutical composition, particularly sublingual, that bypasses hepatic metabolism, enhancing bioavailability and allowing for reduced dosing through direct absorption into the bloodstream.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration of eliglustat is used, then the treatment can be administered conveniently, but the bioavailability is low due to first-pass metabolism
Solution Approach 1:
The patent changes the physical and chemical parameters of eliglustat by converting it to its amorphous hemitartarate form, which has different dissolution and absorption characteristics compared to the crystalline form. This parameter change enables bypassing first-pass metabolism through transmucosal absorption while maintaining administration convenience.
Solution Approach 2:
The patent uses an amorphous solid dispersion system as an intermediary载体 that facilitates the dissolution and absorption of eliglustat through the mucosal membrane. This intermediary system enables the drug to enter systemic circulation directly without undergoing hepatic first-pass metabolism.
2Reliability
If enzyme replacement therapy is used, then disease progression can be reversed or halted, but the treatment requires frequent intravenous infusions and is expensive
Solution Approach 1:
The patent extracts the therapeutic benefit of eliglustat (substrate reduction therapy) and delivers it through a simplified transmucosal route, separating the drug delivery system from the complex intravenous infusion requirement while maintaining disease control efficacy.
Solution Approach 2:
The patent employs a simple dissolvable film formulation that can be discarded after use, replacing the need for expensive, complex, and reusable intravenous infusion equipment. The film dissolves in the mouth, providing a disposable, single-use delivery system.
3Reliability
If high dose oral eliglustat is administered to overcome low bioavailability, then therapeutic effect can be achieved, but the dosing regimen becomes complex based on CYP2D6 genotype
Solution Approach 1:
The patent extracts eliglustat from the complex oral dosing system and delivers it through transmucosal absorption, eliminating the need for genotype-based dosing adjustments and CYP2D6 metabolism considerations while maintaining therapeutic efficacy.
Solution Approach 2:
By changing the administration route from oral to transmucosal and using the amorphous hemitartarate form, the patent alters the bioavailability parameter dramatically, allowing for reduced dosing without requiring complex genotype-based dosing regimens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transmucosal administration of eliglustat achieves significantly improved bioavailability and faster pharmacological effects, enabling dose reduction and simplifying the dosing regimen by avoiding gastrointestinal and hepatic metabolism.
Implementation Method 1
A transmucosal pharmaceutical composition, particularly sublingual, that bypasses hepatic metabolism, enhancing bioavailability and allowing for reduced dosing through direct absorption into the bloodstream
Data Source
AI summary
The present invention relates to a pharmaceutical composition comprising glucosylceramide synthase inhibitor and a one or more pharmaceutically acceptable excipients. The present invention specifically relates to a sublingual pharmaceutical composition of eliglustat or a pharmaceutically acceptable salt thereof and a one or more pharmaceutically acceptable excipients. Moreover, the present invention further relates to a pharmaceutical composition of eliglustat or a pharmaceutically acceptable salt thereof which is used in the treatment of individual with lysozymal storage diseases selected from the group consisting of, Gaucher disease, Sphingolipidoses, Farber disease, Krabbe disease, Fabry disease, Schindler disease, Tay–Sachs disease and Niemann-Pick disease.